Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects

NCT07323680 | Completed Phase 1 FDA Drug

• 1 other identifier: Rho-11-003
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare the safety, pharmacokinetics, and pharmacodynamic effects of aspirin administered intravenously with aspirin administered orally.

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• Change in serum thromboxane B2 from baseline

  Change in serum thromboxane B2 from baseline to 180 minutes post treatment

  1 hour before dosing and 2, 5, 10, 20, 30, 45, 60, and 180 minutes post dosing]

Secondary Outcomes (4)

• Urinary 11-dehydro-TXB2 levels

  Every 12 hours from 24 hours prior to dosing to 72 hours after dosing.

• Urinary 2,3-dinor-6-keto-PGF1alpha

  Every 12 hours from 24 hours prior to dosing to 72 hours after dosing.

• Acetylsalicylic Acid Plasma Pharmacokinetics

  1 hour prior to dosing, and 1,3,5,10,15,20,30, and 45 minutes and 1,1.5,2,3,6,8, and 24 hours postdosing.

• Salicylic Acid Plasma Pharmacokinetics

  1 hour prior to dosing, and 1,3,5,10,15,20,30, and 45 minutes and 1,1.5,2,3,6,8, and 24 hours postdosing.

Study Arms (2)

Rho-11 administered in Period 1, oral aspirin administered in Period 2

EXPERIMENTAL

Drug: 325 mg Oral Aspirin; Drug: 325 mg aspirin by rapid IV push

Oral aspirin administered in Period 1, Rho-11 administered in Period 2

EXPERIMENTAL

Drug: 325 mg Oral Aspirin; Drug: 325 mg aspirin by rapid IV push

Interventions

325 mg Oral Aspirin DRUG

Drug: aspirin 325mg • Subjects will be administered 325 mg aspirin orally

Oral aspirin administered in Period 1, Rho-11 administered in Period 2; Rho-11 administered in Period 1, oral aspirin administered in Period 2

325 mg aspirin by rapid IV push DRUG

Drug: Rho-11 Subjects will be administered 325 mg aspirin by rapid IV push

Also known as: Rho-11

Oral aspirin administered in Period 1, Rho-11 administered in Period 2; Rho-11 administered in Period 1, oral aspirin administered in Period 2

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Each subject must meet all of the following criteria to be enrolled in this study:
• Healthy males and non-pregnant and no breast-feeding females, ≥ 18 and ≤ 55 years of age (on the day of Informed Consent).
• Non-smokers or past smokers (having ceased smoking at least 6 months before the first dosing).
• Body Mass Index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2 on the day of screening.
• The subject is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead electrocardiogram (ECG) results, and physical examination findings at Screening.
• The subject has a hemoglobin level with the following acceptable range at Screening: (Male: 12.8 to 17.4 g/dL (128 to 174 g/L); Female: 10.8 to 15.0 g/dL (108 to 150 g/L).
• The subject has liver function tests within normal limits or has results that do not show clinically significant abnormalities, as judged by the investigator at Screening.
• The subject has estimated glomerular filtration rate eGFR (CKD-EPI) ≥50 mL/min (0.833mL/sec/1.73m2) at Screening.
• Acceptance of use of contraceptive measures during the whole study by both female and male subjects.
• The subject agrees to comply with all protocol requirements.
• The subject can provide written informed consent.
• The subject must fluently speak and understand Czech.

You may not qualify if:

• Subjects meeting any of the following criteria will be excluded from the study:
• The subjects has had any major illness within 3 months before dosing with study drug or any significant ongoing chronic medical illness, as judged by the investigator.
• The subjects has a history of active deep vein thrombosis and/or thromboembolic disorder, including history of hypothrombinemia and vitamin K deficiency.
• The subject has a history of neuropsychiatric disease, hypertension, cardiac failure, cerebrovascular disease, chronic respiratory disease, asthma, nasal polyps associated with asthma, hepatic or renal impairment, recent dehydration (within last 30 days), gout thyrotoxicosis or systemic lupus erythematosus and other connective tissue disorders.
• The subject has a history of gastrointestinal bleeding or has active gastrointestinal disease that could affect drug absorption.
• The subject has a history of hemorrhagic disorder.
• Prothrombin time or activated partial thromboplastin time level outside the normal range at screening and check-in.
• The subject has an increased risk of bleeding including but not limited to: any history of a clinically significant bleeding problem, any recent (within 30 days preceding the first dose of study drug) major trauma, platelet count \<100,000 mm3
• The subject has a history of glucose-6-phosphate dehydrogenase deficiency.
• The subject has a recent history of tooth extraction within 3 weeks before dosing with study drug.
• The subject is a smoker or has used nicotine-containing products (e.g., snuff, nicotine patch, nicotine chewing gum, mock cigarettes, inhalers, or "vape" devices) within 6 months before the first dose of study drug and throughout the study (including the washout period).
• The subject has a history of alcohol abuse or drug addiction within 1 year prior to check-in or excessive alcohol consumption (regular alcohol intake \>21 units per week for male subjects and \>14 units of alcohol per week for female subjects), or use of alcohol 48 hours before dosing with study drug.
• The subject has a positive test result for drugs of abuse, alcohol, or cotinine at screening or before dosing with study drug.
• The subject has used any prescription (excluding hormonal birth control) or over-the-counter medications, including fish oil and other herbal or nutritional supplements and, in particular, aspirin (no aspirin-containing medications allowed at all), nonsteroidal anti-inflammatory agents (No NSAIDS allowed at all, and no acetaminophen, diclofenac, ketorolac allowed), or anticoagulation therapy within 14 days before dosing with study drug and throughout the entire study period (including the washout period).
• The subject has received vaccination against Varicella zoster within 6 weeks before dosing with study drug.

Sponsors & Collaborators

• Rhoshan Pharmaceuticals Inc: lead

Study Sites (1)

Quinta-Analytica s.r.o.

Prague, Czechia

Location

MeSH Terms

Interventions

Aspirin; DNA modification methylase phi3TII, Bacteriophage phi-3T

Intervention Hierarchy (Ancestors)

Salicylates; Hydroxybenzoates; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Study Officials

• Joseph Purvis, MD

  jpurvis@rhoshanpharma.com

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 18, 2025
• First Posted: January 7, 2026
• Study Start: June 15, 2025
• Primary Completion: July 7, 2025
• Study Completion: December 12, 2025
• Last Updated: June 12, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

CZ (1)